Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2016 · 10-Q
Revenue$29.65M$29.65M+103.0% vs Q1 2015 Net Income$6.61M$6.61M+776.4% vs Q1 2015 EPS Diluted$0.30$0.30+650.0% vs Q1 2015 Operating Income$15,096,000+350.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived$12,876,000+70.1% Margins · derivedOperating margin50.9%+28.0 pt vs Q1 2015
Net margin22.3%+17.1 pt vs Q1 2015
ended Mar 31, 2016 · filed May 9, 2016 · 39 d after period end